Loading…
Abrdn Life Sciences Investors is projected to rise to $27.44 by 2027, a +35% move from its current price of $20.28. HQL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $20.02 | $20.29 | $20.55 | +0.03% |
| Jul 13 | $19.92 | $20.29 | $20.67 | +0.06% |
| Jul 14 | $19.84 | $20.30 | $20.76 | +0.08% |
| Jul 15 | $19.78 | $20.30 | $20.84 | +0.11% |
| Jul 16 | $19.72 | $20.31 | $20.91 | +0.14% |
| Jul 17 | $19.67 | $20.31 | $20.98 | +0.17% |
| Jul 18 | $19.62 | $20.32 | $21.04 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.62 | $20.32 | $21.04 | +0.19% |
| Week 2 | $19.38 | $20.36 | $21.38 | +0.39% |
| Week 3 | $19.21 | $20.40 | $21.66 | +0.58% |
| Week 4 | $19.06 | $20.44 | $21.91 | +0.78% |
| Week 5 | $18.94 | $20.48 | $22.13 | +0.97% |
| Week 6 | $18.84 | $20.52 | $22.34 | +1.17% |
| Week 7 | $18.75 | $20.56 | $22.54 | +1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Abrdn Life Sciences Investors is a closed-ended equity mutual fund managed by abrdn Inc. The fund invests in public equity markets across the globe with a focus on the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies and employs fundamental analysis that emphasizes factors such as market position for services or products, management experience, technological expertise, and the ability to generate funds internally or secure external capital to finance growth.
The fund benchmarks its portfolio against the NASDAQ Biotech Index and the S&P 500 Index.
Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
HQL is a closed-ended equity mutual fund in the Financial Services category with a current price of $19.76 and a market cap of $600.86M. It is ranked 2771 by market position and trades in a space where growth-focused small-cap companies are its core exposure.
The current price sits within a context of technicals that show bullish tendencies, supported by a 30-day range of $18.07 to $21.61 and a bullish sentiment signal. The fund’s target exposure is globally diversified within the life sciences ecosystem, and long-run forecasts project substantial upside across multiple years, illustrated by rising average prices and high ROI potential through 2050.
A major floor 26.6% below — a decisive break under it would weaken the trend.
The nearest floor, 18.6% below — buyers have tended to step in here.
Price is pressing into resistance (2.7% away) — a breakout level to watch.
A major ceiling 16.0% above — clearing it would confirm fresh momentum.
Key HQL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HQL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.49 | Sell | $20.40 | Sell |
| MA 10 | $20.16 | Buy | $20.04 | Buy |
| MA 20 | $19.02 | Buy | $19.35 | Buy |
| MA 50 | $18.13 | Buy | $18.41 | Buy |
| MA 100 | $17.50 | Buy | $17.77 | Buy |
| MA 200 | $17.11 | Buy | $16.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.30 | Neutral |
| Stoch RSI (14) | 25.63 | Neutral |
| CCI (20) | 73.75 | Neutral |
| Williams %R (14) | -22.09 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 8.86 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 77.91 | Neutral |
| TRIX (15) | 0.54 | Buy |
| Awesome (5,34) | 2.22 | Buy |
| Ultimate (7,14,28) | 66.54 | Neutral |
| Momentum (10) | 1.25 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 20.77 | Sell |
| ADX (14) | 39.12 | Buy |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is bullish with the RSI at 80 and the price currently at $19.76, above the SMA50 of $17.71 and above the SMA200 of $16.86. Support is at $16.51 and resistance at $19.76, with the stock trading in a 30-day range from $18.07 to $21.61.
These near-term indicators suggest upside potential within the current range, supported by a bullish technical bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.87 | $20.28 | $27.00 | 0% | Neutral | |
| $22.48 | $27.44 | $35.04 | +35% | Bullish | |
| $23.90 | $29.74 | $38.99 | +47% | Bullish | |
| $26.45 | $33.42 | $44.75 | +65% | Bullish | |
| $29.81 | $38.16 | $52.02 | +88% | Bullish | |
| $34.23 | $44.35 | $61.42 | +119% | Bullish | |
| $41.79 | $54.76 | $76.91 | +170% | Bullish | |
| $46.81 | $61.99 | $88.19 | +206% | Bullish | |
| $51.76 | $69.23 | $99.66 | +241% | Bullish | |
| $54.66 | $73.79 | $107.41 | +264% | Bullish | |
| $89.95 | $126.66 | $193.21 | +525% | Bullish | |
| $167.06 | $252.29 | $412.53 | +11.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.87 | $20.28 | $24.22 | +0.00% |
| August 2026 | $17.39 | $20.36 | $24.35 | +0.40% |
| September 2026 | $17.68 | $20.80 | $25.07 | +2.14% |
| October 2026 | $18.33 | $21.64 | $26.26 | +4.08% |
| November 2026 | $18.45 | $21.87 | $26.68 | +1.05% |
| December 2026 | $18.51 | $22.01 | $27.00 | +0.66% |
Click any year to see its month-by-month HQL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, HQL is projected to trade between $15.87 and $27.00, averaging $20.28 — a potential gain of 0% from today's $20.28. Price action looks broadly range-bound.
Abrdn Life Sciences Investors's 2027 outlook centres on $27.44, within a $22.48 to $35.04 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, HQL could reach as high as $38.99, with a base case around $29.74 and support toward $23.90 — roughly +47% from $20.28. Momentum favours further upside here.
Expect HQL to range from $26.45 to $44.75 through 2029. The $33.42 average target implies a +65% move from current prices. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The HQL price prediction for 2030 points to an average of $38.16 (low $29.81, high $52.02) — a potential gain of +88% on today's $20.28. Momentum favours further upside here.
In 2031, HQL is projected to trade between $34.23 and $61.42, averaging $44.35 — a potential gain of +119% from today's $20.28. That is up +16% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Abrdn Life Sciences Investors's 2032 outlook centres on $54.76, within a $41.79 to $76.91 range. That is up +23% on the projected 2031 average. That marks a +170% change versus current levels. Momentum favours further upside here.
By 2033, HQL could reach as high as $88.19, with a base case around $61.99 and support toward $46.81 — roughly +206% from $20.28. Buyers look set to stay in control over this stretch.
Expect HQL to range from $51.76 to $99.66 through 2034. The $69.23 average target implies a +241% move from current prices. That is up +12% on the projected 2033 average. Momentum favours further upside here.
The HQL price prediction for 2035 points to an average of $73.79 (low $54.66, high $107.41) — a potential gain of +264% on today's $20.28. Buyers look set to stay in control over this stretch.
In 2040, HQL is projected to trade between $89.95 and $193.21, averaging $126.66 — a potential gain of +525% from today's $20.28. That is up +72% on the projected 2035 average. Momentum favours further upside here.
Abrdn Life Sciences Investors's 2050 outlook centres on $252.29, within a $167.06 to $412.53 range. That is up +99% on the projected 2040 average. That marks a +11.4x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in HQL today (≈ 49.309665 HQL) could be worth
$12,440.58
+$11,440.58 (+1144%) by 2050 · US Dollar
Based on the average projected HQL price of $252.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HQLwould be worth at today's price.
$1,000 invested in HQL on Jul 10, 2025 (≈ 74.626868 HQL) would be worth
$1,513.43
+$513.43 (+51.3%) today · 1.51× · US Dollar
Based on a HQL entry price of $13.4 vs. today's $20.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.12 | $1,007.95 | +0.8% |
| 1 month ago | $16.51 | $1,228.35 | +22.8% |
| 3 months ago | $17.16 | $1,181.82 | +18.2% |
| 6 months ago | $16.75 | $1,210.75 | +21.1% |
| 1 year ago | $13.4 | $1,513.43 | +51.3% |
| All time (5.0y) ago | $20.81 | $974.53 | -2.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HQL forecast.
Our base-case forecast reaches $41.00 around 2031.
Implied market cap at $41.00: $1.25B
The multi-year forecast lays out a path of steady upside with a bullish sentiment prevailing across the longer horizon. In 2026, the average price is projected at $19.76 with a min of $15.87 and a max of $26.43, and ROI of 0%. The trajectory then strengthens with 2027 at an average of $26.45 and ROI of 33.8%, 2028 at $27.71 and ROI 40.3%, and 2029 at $31.16 and ROI 57.7%.
By 2030 the average is forecast at $35.31 with ROI 78.7%, and by 2031 at $39.49 with ROI 99.8%. The growth continues to 2032 ($48.91, ROI 147.5%), 2033 ($55.29, ROI 179.8%), 2034 ($60.27, ROI 205%), and 2035 ($64.55, ROI 226.7%). Longer horizons show even greater upside: 2040 average $105.84 with ROI 435.6%, and 2050 average $207.69 with ROI 951.1%.
The forecast indicates bullish momentum into the 2030s and beyond, with substantially higher upside in later years. While the numbers imply strong upside potential, these are estimates and not guarantees, and investors should consider the volatility embedded in the life sciences equity space as reflected by the 30% annualized volatility. Risk remains that actual results diverge from these projections.
Tap a question to reveal the answer.
Avg $35.31; min $27.57; max $48.16; ROI 78.7; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward, with Avg prices rising to $26.45 (2027), $27.71 (2028), $31.16 (2029), and up to $35.31 (2030) with increasing ROI (e.g., 78.7% by 2030 and 951.1% by 2050). 2026 is neutral with Avg $19.76 and ROI 0. These are estimates, not guarantees.
Yes. The 2040 forecast lists an average price of $105.84 and a max of $161.49, with ROI 435.6%, indicating prices above $100 are projected in that horizon.
Current price is $19.76 and market cap is $600.86M.
Avg $207.69; min $137.50; max $339.66; ROI 951.1; sentiment BULLISH.
Abrdn Life Sciences Investors Community Discussion
0Share your Abrdn Life Sciences Investors price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.